GlaxoSmithKline plc - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 477 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

GlaxoSmithKline plc - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'GlaxoSmithKline plc - Product Pipeline Review - 2014', provides an overview of the GlaxoSmithKline plc's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of GlaxoSmithKline plc's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of GlaxoSmithKline plc including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of GlaxoSmithKline plc's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the GlaxoSmithKline plc's pipeline products

Reasons to buy

- Evaluate GlaxoSmithKline plc's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of GlaxoSmithKline plc in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the GlaxoSmithKline plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of GlaxoSmithKline plc and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of GlaxoSmithKline plc
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of GlaxoSmithKline plc and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
GlaxoSmithKline plc Snapshot 9
GlaxoSmithKline plc Overview 9
Key Information 9
Key Facts 9
GlaxoSmithKline plc - Research and Development Overview 10
Key Therapeutic Areas 10
GlaxoSmithKline plc - Pipeline Review 24
Pipeline Products by Stage of Development 24
Pipeline Products - Monotherapy 25
Pipeline Products - Combination Treatment Modalities 26
Pipeline Products - Partnered Products 27
Pipeline Products - Out-Licensed Products 31
GlaxoSmithKline plc - Pipeline Products Glance 33
GlaxoSmithKline plc - Late Stage Pipeline Products 33
GlaxoSmithKline plc - Clinical Stage Pipeline Products 38
GlaxoSmithKline plc - Early Stage Pipeline Products 52
GlaxoSmithKline plc - Drug Profiles 55
(umeclidinium bromide + vilanterol trifenatate) 55
eltrombopag olamine 57
Flu Pandemic Vaccine 60
fluticasone furoate 62
influenza virus vaccine quadrivalent 65
tenofovir disoproxil fumarate 67
trametinib 69
(dabrafenib + trametinib) 72
pazopanib hydrochloride 74
(fluticasone furoate + vilanterol trifenatate) 78
albiglutide 80
alitretinoin 83
ambrisentan 85
astuprotimut-R 87
belimumab 88
darapladib 91
GSK-1437173A 93
GSK-1562902A 95
GSK-2132231A 97
GSK-257049 99
GSK-2696273 102
KD-295 103
lapatinib ditosylate 104
measles, mumps and rubella vaccine (live) 107
mepolizumab 108
ofatumumab 110
recMAGE-A3 + AS15 114
umeclidinium bromide 116
vilanterol trifenatate 118
zanamivir 120
tafenoquine 122
(fluticasone furoate + levocabastine hydrochloride) 124
(fluticasone furoate + umeclidinium) 125
AD-02 126
afuresertib 128
Antisense Oligonucleotide for Transthyretin Amyloidosis 130
batefenterol 131
camicinal 133
dabrafenib 135
danirixin 137
dilmapimod 139
fiboflapon 141
firategrast 143
foretinib 145
GSK-1070806 147
GSK-1278863 148
GSK-1322322 150
GSK-1399686 152
GSK-2140944 153
GSK-217744 154
GSK-2189242A 155
GSK-2231392A 157
GSK-2245035 158
GSK-2269557 160
GSK-2285921 161
GSK-2302024A 163
GSK-2302032A 164
GSK-2330672 165
GSK-2339345 166
GSK-239512 167
GSK-249320 168
GSK-256073 170
GSK-2586184 171
GSK-2586881 173
GSK-2696274 174
GSK-2696275 175
GSK-2789869A 176
GSK-2830929A 177
GSK-2830930A 178
GSK-2838497A 179
GSK-2890457 180
GSK-3196165 181
GSK-598809 183
GSK-692342 185
GSK-732462 187
GSK-933776 188
levocabastine hydrochloride 189
losmapimod 190
mapatumumab 192
maribavir 195
Nimenrix 197
otelixizumab 200
ozanezumab 202
ProCvax 203
Recombinant Vector Vaccine for Malaria 204
retosiban 206
rilapladib 208
ronacaleret hydrochloride 209
S. Pneumoniae Next Generation Vaccine 211
trametinib + dabrafenib + panitumumab 212
trametinib + uprosertib 213
afuresertib + trametinib 215
GSK-2302025A 216
GSK-2636771 217
GSK-525762 218
(amlodipine + enalapril maleate) 219
(amlodipine + losartan) 221
(amlodipine + rosuvastatin) 222
(candesartan cilexetil + hydrochlorothiazide) 223
(fluticasone furoate + umeclidinium + vilanterol) 224
AD-01 226
AD-03 227
Ad35-GRIN Vaccine + Adjuvanted HIV Vaccine 229
DENV-1 PIV 230
epelsiban besylate 231
exenatide 233
FP-1039 234
GLPG-0555 236
GSK-1070916A 238
GSK-1940029 239
GSK-1995057 240
GSK-2130579A 241
GSK-2241658A 242
GSK-2256098 243
GSK-2256098 + trametinib 244
GSK-2256294 245
GSK-2315698 246
GSK-2315698 + GSK-2398852 247
GSK-2330672 + GSK-1614235 248
GSK-2374697 249
GSK-2392019A 250
GSK-2392102A 251
GSK-2392103A 252
GSK-2392105A 253
GSK-2392106A 254
GSK-2398852 255
GSK-2434735 256
GSK-2647544 257
GSK-2654909A 258
GSK-2654911A 259
GSK-2789868-A 260
GSK-2793660 261
GSK-2798745 262
GSK-2800528 263
GSK-2816126 264
GSK-2838232 265
GSK-2838500A 266
GSK-2838501A 267
GSK-2849330 268
GSK-2849466 269
GSK-2857916 270
GSK-2862277 271
GSK-2878175 272
GSK-2879552 273
GSK-2881078 274
GSK-2981710 275
GSK-3003891A 276
GSK-3003892A 277
GSK-3003893A 278
GSK-3003895A 279
GSK-3003896A 280
GSK-3003898A 281
GSK-3003899A 282
GSK-3050002 283
GSK-3117391 284
GSK-3206640A 285
GSK-3206641-A 286
HIV Prophylactic Vaccine 287
HIV Vaccine 288
omipalisib 289
RSV-001 290
TerCvax 291
uprosertib 293
Antibody Drug Conjugate for Cancer 294
BLyS-Gelonin Fusion Toxin for Cancer 295
Cancer Vaccine 296
Ebola And Marburg Vaccine 297
GSK-2041706 298
GSK-2225745 299
GSK-2578215A 300
GSK-2656157 302
IMP-731 303
Influenza Vaccine 305
Monoclonal Antibodies to Activate OX40 Receptors for Cancer 306
Monophosphoryl Lipid A Vaccine for Alzheimer's Disease 307
Proteosome-Based Vaccine for Alzheimer's Disease 308
Small Molecule1 to Inhibit Histone Methyltransferases for Cancer 309
Small Molecule2 to Inhibit Histone Methyltransferases for Cancer 310
Small Molecule3 to Inhibit Histone Methyltransferases for Cancer 311
Small Molecules For Malaria 312
Small Molecules to Inhibit Gyrase for Mycobacterium Tuberculosis Infections 313
Tuberculosis Vaccine 314
Antibodies Targeting an Immune Checkpoint for Cancer 315
Drug for Chronic Liver Disease 316
Drug to Inhibit Kynurenine 3-Monooxygenase for Acute Pancreatitis 317
GSK-J1 318
Small Molecule for Tuberculosis 319
Small Molecule to Inhibit Histone Deacetylases for Cancer 320
Small Molecules to Inhibit Falcipain for Malaria 321
Small Molecules to Inhibit InhA for Tuberculosis 322
Small Molecules to Inhibit Leucyl-tRNA Synthetase for Tuberculosis 323
Small Molecules to Inhibit RNA Polymerase for Hepatitis C 324
GlaxoSmithKline plc - Pipeline Analysis 325
GlaxoSmithKline plc - Pipeline Products by Target 325
GlaxoSmithKline plc - Pipeline Products by Route of Administration 332
GlaxoSmithKline plc - Pipeline Products by Molecule Type 334
GlaxoSmithKline plc - Pipeline Products by Mechanism of Action 336
GlaxoSmithKline plc - Recent Pipeline Updates 344
GlaxoSmithKline plc - Dormant Projects 413
GlaxoSmithKline plc - Discontinued Pipeline Products 434
Discontinued Pipeline Product Profiles 435
GlaxoSmithKline plc - Company Statement 447
GlaxoSmithKline plc - Locations And Subsidiaries 450
Head Office 450
Other Locations & Subsidiaries 450
GlaxoSmithKline plc - Key Manufacturing Facilities 461
Appendix 462
Methodology 462
Coverage 462
Secondary Research 462
Primary Research 462
Expert Panel Validation 462
Contact Us 463
Disclaimer 463

List of Tables
GlaxoSmithKline plc, Key Information 23
GlaxoSmithKline plc, Key Facts 23
GlaxoSmithKline plc - Pipeline by Indication, 2014 25
GlaxoSmithKline plc - Pipeline by Stage of Development, 2014 38
GlaxoSmithKline plc - Monotherapy Products in Pipeline, 2014 39
GlaxoSmithKline plc - Combination Treatment Modalities in Pipeline, 2014 40
GlaxoSmithKline plc - Partnered Products in Pipeline, 2014 41
GlaxoSmithKline plc - Partnered Products/ Combination Treatment Modalities, 2014 42
GlaxoSmithKline plc - Out-Licensed Products in Pipeline, 2014 45
GlaxoSmithKline plc - Out-Licensed Products/ Combination Treatment Modalities, 2014 46
GlaxoSmithKline plc - Pre-Registration, 2014 47
GlaxoSmithKline plc - Filing rejected/Withdrawn, 2014 48
GlaxoSmithKline plc - Phase III, 2014 49
GlaxoSmithKline plc - Phase II, 2014 52
GlaxoSmithKline plc - Phase I, 2014 59
GlaxoSmithKline plc - Preclinical, 2014 66
GlaxoSmithKline plc - Discovery, 2014 68
GlaxoSmithKline plc - Pipeline by Target, 2014 339
GlaxoSmithKline plc - Pipeline by Route of Administration, 2014 347
GlaxoSmithKline plc - Pipeline by Molecule Type, 2014 349
GlaxoSmithKline plc - Pipeline Products by Mechanism of Action, 2014 350
GlaxoSmithKline plc - Recent Pipeline Updates, 2014 358
GlaxoSmithKline plc - Dormant Developmental Projects,2014 427
GlaxoSmithKline plc - Discontinued Pipeline Products, 2014 448
GlaxoSmithKline plc, Other Locations 464
GlaxoSmithKline plc, Subsidiaries 464
GlaxoSmithKline plc, Key Manufacturing Facilities 475